- Home
- UAA vs IBRX Comparison
UAA vs IBRX Comparison
Compare UAA & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAA
- IBRX
- Stock Information
- Founded
- UAA 1996
- IBRX 2014
- Country
- UAA United States
- IBRX United States
- Employees
- UAA N/A
- IBRX N/A
- Industry
- UAA Apparel
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UAA Consumer Discretionary
- IBRX Health Care
- Exchange
- UAA Nasdaq
- IBRX Nasdaq
- Market Cap
- UAA 2.2B
- IBRX 2.3B
- IPO Year
- UAA N/A
- IBRX N/A
- Fundamental
- Price
- UAA $4.81
- IBRX $2.46
- Analyst Decision
- UAA Hold
- IBRX Strong Buy
- Analyst Count
- UAA 20
- IBRX 6
- Target Price
- UAA $6.88
- IBRX $9.83
- AVG Volume (30 Days)
- UAA 8.6M
- IBRX 9.3M
- Earning Date
- UAA 11-06-2025
- IBRX 11-11-2025
- Dividend Yield
- UAA N/A
- IBRX N/A
- EPS Growth
- UAA N/A
- IBRX N/A
- EPS
- UAA 0.23
- IBRX N/A
- Revenue
- UAA $5,114,713,000.00
- IBRX $56,600,000.00
- Revenue This Year
- UAA N/A
- IBRX $629.94
- Revenue Next Year
- UAA $2.72
- IBRX $109.91
- P/E Ratio
- UAA $21.21
- IBRX N/A
- Revenue Growth
- UAA N/A
- IBRX 4227.22
- 52 Week Low
- UAA $4.72
- IBRX $1.83
- 52 Week High
- UAA $11.89
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- UAA 44.86
- IBRX 49.22
- Support Level
- UAA $4.72
- IBRX $2.30
- Resistance Level
- UAA $4.89
- IBRX $2.50
- Average True Range (ATR)
- UAA 0.14
- IBRX 0.12
- MACD
- UAA 0.01
- IBRX -0.01
- Stochastic Oscillator
- UAA 30.88
- IBRX 47.30
About UAA Under Armour Inc.
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and elsewhere. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. The Baltimore-based company was founded in 1996 and is led by controlling shareholder Kevin Plank.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.